Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed or refractory follicular lymphoma based on first data from single-arm US cohort of phase III CELESTIMO study1 Data from subcutaneous Lunsumio plus Polivy reinforce its outpatient, chemotherapy-free potential in people with R/R large B-cell lymphoma2,3 Results highlight the potential of innovative Lunsumio combination regimens to offer improved outcomes for more people with lymphoma earlier in their diseaseBasel, 8 December 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new data highlighting the potential of Lunsumio® (mosunetuzumab) in earlier treatment lines for people living with different types of lymphoma, presented at the 67th American Society of Hematology Annual Meeting and Exposition, 6-9 December 2025 in Orlando, Florida,...

GREENVILLE, S.C., Dec. 08, 2025 (GLOBE NEWSWIRE) — United Community Banks, Inc. (NYSE: UCB) (the “Company”) today announced that the Company’s Board of Directors approved a common stock repurchase program, authorizing the repurchase of up to $100.0 million of its outstanding common stock on the open market, in privately negotiated transactions, or in any other manner that complies with the provisions of the Securities Exchange Act of 1934, as amended (the “Stock Repurchase Program”). The Company may make repurchases under the Stock Repurchase Program from time to time beginning after the expiration of its current common stock repurchase program on December 31, 2025, and ending on December 31, 2026. The Company has repurchased $44 million of shares in 2025 under its current common stock repurchase program. The Stock Repurchase Program...

Media Release COPENHAGEN, Denmark; December 8, 2025Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT), highlighting its potential as a treatment option for those unsuitable for chemotherapy Additional early data show promising efficacy of epcoritamab combination regimens in patients with RT Results underscore the potential of epcoritamab as a versatile therapy for a broad range of B-cell malignanciesGenmab A/S (Nasdaq: GMAB) today announced new and updated data from three arms of the ongoing Phase 1b/2 EPCORE® CLL-1 trial (NCT04623541) evaluating the efficacy and safety of epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy and in combination for the treatment of patients with Richter...

LONG BEACH, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) — Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a global leader in launch services and space systems, today announced the Neutron launch vehicle’s innovative “Hungry Hippo” captive fairing has successfully completed qualification testing and is enroute to Virginia for Neutron’s first launch. Dubbed the Hungry Hippo, Neutron’s fairing halves remain attached to the rocket’s first stage throughout launch and landing back to Earth – a world-first for a reusable commercial rocket. Whereas typical rockets’ fairing halves fall away during launch and are disposable or require collection at sea for reuse, Neutron’s fairing halves open to release the rocket’s second stage and mission payload before closing again to return Neutron to Earth as a single reusable vehicle...

REDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) — Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced positive results from its completed Phase 2 trial evaluating burixafor (GPC-100) in combination with propranolol and granulocyte colony-stimulating factor (G-CSF) for the mobilization of hematopoietic progenitor cells (HPCs) in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation (AHCT). The data, which showed that approximately 90% of study participants achieved the primary endpoint, were presented today in an oral session at the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. Burixafor is an investigational small molecule that blocks CXCL12 binding to CXCR4 receptors on HPCs,...

The Brewster Wind Project is Now Yəyus EnergyFeaturing artwork by local Wei Wai Kum artist James KwaksistalaCampbell River, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) — Capstone Infrastructure Corporation (“Capstone”) and Wei Wai Kum First Nation (“Wei Wai Kum”) are proud to announce the official renaming of the Brewster Wind Project to Yəyus Energy (“Yet-yoos”), reflecting our shared commitment to renewable energy, community and cultural empowerment, and partnership. Capstone and Wei Wai Kum First Nation: Partnership for Progress This transformative project is being developed in collaboration between Capstone and Wei Wai Kum First Nation in the traditional territory of Ligʷiłdaxʷ peoples. The formerly named Brewster Wind Project secured a 30-year Electricity Purchase Agreement in BC Hydro’s...

MONTREAL, Dec. 08, 2025 (GLOBE NEWSWIRE) — CN (TSX: CNR) (NYSE: CNI) announced today a new monthly record for grain movement in November. CN moved over 3.28 million metric tonnes of grain from Western Canada last month, higher by 230,000 metric tonnes from its previous set record for November in 2020. This is CN’s third consecutive record month for grain movement. “Achieving a third consecutive record month of grain movement demonstrates what’s possible with strong customer collaboration, thoughtful planning, and a dedicated team of railroaders.” – Janet Drysdale, Executive Vice-President and Chief Commercial Officer at CN. CN Winter PlanCN continues to execute its winter operations plan across the network as the colder months have begun. For more information and details about how the Company has put proactive solutions...

NJBIZ Power ListTevogen named in the NJBIZ Business Power ListWARREN, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) — Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that it has been named to the 2025 New Jersey Power List by NJBIZ, recognizing the most influential organizations shaping New Jersey’s economic and innovation landscape. NJBIZ highlighted Tevogen’s pioneering ExacTcell™ platform, its advancing pipeline in infectious diseases, oncology, and neurology, and the Company’s internally developed PredicTcell™ AI technology, designed to accelerate target prediction and improve clinical outcomes. The publication also mentioned Tevogen’s previously projected near-term commercial potential, including an anticipated ~$1 billion in first-year specialty-care revenue and a cumulative...

64% MMR achievement by 24 weeks across all efficacy evaluable patients  75% MMR achievement by 24 weeks in efficacy evaluable patients at doses >320mg QD Encouraging safety/tolerability profile maintained with longer duration of treatment Company to host investor update call today at 4:30pm ET FOSTER CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq: TERN), a clinical-stage oncology company, today announced that updated and expanded data from the ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor, in patients with previously treated chronic myeloid leukemia (CML) are being presented today at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 6-9, 2025 in Orlando, FL. The company will host...

Additional Cash Deployment Demonstrates Confidence in Zcash’s Privacy-Enabled Architecture, Which the Company Believes Is Well-Suited for Institutional Use LAKEWOOD, NJ, Dec. 08, 2025 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: RELI) (“Reliance”, “we” or the “Company”) today announced that it has deployed additional cash to increase its Zcash (ZEC) position. This additional allocation to the Company’s Digital Asset Treasury (“DAT”) reflects the Company’s internal view that ZEC may be an institutionally adaptable and technologically resilient privacy-enabled digital asset and may play a meaningful role in its long-term treasury strategy. Zcash’s dual architecture which combines transparent auditability with optional privacy in the Company’s view supports its appeal to organizations seeking digital assets that can be...